ArQule partner halts lung cancer drug trial

Published on Medical Design Technology (http://www.mdtmag.com)

ArQule partner halts lung cancer drug trial

Mass High Tech: The Journal of New England Technology

Woburn-based biotech company ArQule Inc. has learned that partner Kyowa Hakko Kirin Co., Ltd., which has exclusive development rights to ArQule's lead product candidate tivantinib in Japan, has <u>suspended patient enrollment</u> [1] in its ongoing Phase 3 trial dubbed ATTENTION.

Source URL (retrieved on 05/18/2013 - 11:15pm):

 $\frac{http://www.mdtmag.com/news/2012/08/arqule-partner-halts-lung-cancer-drugtrial?qt-video_of_the_day=0$

Links:

[1] http://www.faqs.org/sec-filings/120829/ARQULE-INC 8-K/#ixzz2539Yc8dq

Page 1 of 1